Cipla shares broke out above ₹1,580–₹1,590 on strong volumes, with technical indicators signaling further gains.

An update from Theravance Biopharma ( (TBPH) ) is now available. On August 15, 2025, Theravance Biopharma and Mylan entered into a Settlement Agreement with Cipla to resolve ongoing patent litigation ...

A malaria drug made by India's Cipla has been pre-qualified by the World Health Organization (WHO), an important step towards its roll-out across Asia, where millions of people are infected with ...

Nomura’s June 2025 analysis shows Indian pharma majors like Sun Pharma, Dr. Reddy’s, Cipla, Lupin, and Zydus posting strong ...

Indian drugmaker Cipla Ltd reported a smaller-than-expected rise in third-quarter profit on Wednesday, as muted sales in the domestic market offset strong demand in the North America.

According to Elara Capital’s Domestic Liquidity Tracker, the changes in pharma and tech were led by HDFC MF, ICICI Prudential MF, and SBI Mutual Fund.

Zee Business analysts Ansh Jogendra Bhilwar and Pooja Tripathi have shared a number of calls for trading and investing today, ...

Union Commerce and Industry Minister Piyush Goyal has discussed strategies to boost competitiveness and strengthen research ...

Dhananjay Sinha of Systematix Group notes US tariffs impact on pharma. A correction is seen in US-exposed companies. Tariff ...

Prices for Indian consumers are expected to come down significantly from the current Rs 17,000-Rs 26,000 monthly.

But new product approvals have been secured, and some Cipla-watchers expect revenues to take a leap in fiscal 2013. Hamied figures Big Pharma might be quite interested in peddling Cipla's growing ...

Palak Pharma’s advocate Samrat Mehta submitted that his client had launched its product containing OMEGA 3 fatty acid and vitamins in 2014. Cipla introduced its product in 2015.